InVivo Therapeutics names new board member
This article was originally published in Scrip
Executive Summary
InVivo Therapeutics, a biomaterials and biotechnology company with a focus on treatment of spinal cord injuries, has named Ann Merrifield to its board of directors. Ms Merrifield was most recently president and chief executive officer at PathoGenetix, a genomics company that developed an automated system for rapid bacterial identification from complex samples. She also previously spent 18 years at Genzyme, serving in a number of leadership roles.